Published on 21/12/2025
How the 90% Confidence Interval Rule Shapes Bioequivalence Decisions
Introduction: The Role of Statistics in Bioequivalence
In bioavailability and bioequivalence (BA/BE) studies, demonstrating therapeutic equivalence between a generic and a reference drug is a regulatory cornerstone. Among various statistical tools, the 90% confidence interval (CI) rule is the universally accepted method for assessing bioequivalence. Regulatory bodies such as the FDA, EMA, and CDSCO require that the 90% CI of the pharmacokinetic parameter ratios—such as Cmax and AUC—fall within a defined equivalence margin to be deemed bioequivalent.
This tutorial breaks down the theory and application of the 90% CI rule, using real-world examples and practical calculations for pharmaceutical and clinical professionals.
Why the 90% Confidence Interval and Not 95%?
In typical hypothesis testing, a 95% CI is used to determine significance. However, in BA/BE studies, the objective is not to show a difference but to demonstrate equivalence. This leads to the use of the Two One-Sided Tests (TOST) procedure, where two one-sided 5% tests are applied. The result is a 90% CI that must fall entirely within the regulatory acceptance limits—usually 80.00% to 125.00% on a log-transformed scale.
Statistical Foundation of the 90% CI Rule
The
- Cmax: Maximum plasma concentration
- AUC0-t: Area under the curve to the last measurable concentration
- AUC0-∞: Area under the curve extrapolated to infinity
All parameters are log-transformed prior to analysis to stabilize variances and improve normality, which is a key assumption in parametric statistics.
Step-by-Step Calculation of 90% Confidence Interval
Below is a simplified workflow for calculating the 90% CI in a 2×2 crossover design:
- Log-transform the individual subject values for Cmax, AUC0-t, etc.
- Calculate the difference in means (log-transformed) between test and reference.
- Estimate the standard error (SE) from the residual mean square of ANOVA.
- Calculate the 90% CI using:
CI = (mean difference) ± tα,df × SE - Exponentiate the lower and upper bounds to return to the original scale.
Dummy Example of CI Calculation
| Parameter | GMR (%) | Lower 90% CI | Upper 90% CI | Result |
|---|---|---|---|---|
| Cmax | 95.2 | 88.1 | 103.0 | Pass |
| AUC0-t | 98.4 | 91.6 | 104.8 | Pass |
Since both 90% CIs fall within the 80.00–125.00% interval, the formulations are considered bioequivalent.
Regulatory Acceptance Range and Adjustments
The default acceptance range for the 90% CI is 80.00–125.00%. However, exceptions apply:
- Narrow Therapeutic Index (NTI) drugs: Some agencies, such as the EMA, tighten this range to 90.00–111.11% for AUC.
- Highly Variable Drugs (HVDs): The range may be widened using reference-scaled average bioequivalence (RSABE), especially when within-subject variability (CV%) exceeds 30%.
Refer to current HVD-specific guidelines from ISRCTN for more information on scaled acceptance criteria.
Visualizing Confidence Interval Decision Making
A graphical representation often helps illustrate the decision process:
- If the 90% CI lies entirely within 80–125%, then BE is established.
- If the CI crosses the boundary (e.g., 78–122%), then BE is not established—even if the GMR is close to 100%.
Common Misconceptions About CI in BE Studies
- Misconception: Passing one parameter (e.g., AUC) is enough.
Reality: All predefined PK parameters must meet CI criteria. - Misconception: Point estimate within limits is sufficient.
Reality: CI, not point estimate alone, determines BE. - Misconception: CI can be calculated on raw data.
Reality: Log-transformed data is mandatory.
Statistical Tools and Software for CI Estimation
Several software packages are validated for calculating 90% CIs in BA/BE studies:
- WinNonlin® (Phoenix): Industry standard with validated statistical engines
- SAS®: Used for complex mixed-model designs and regulatory submissions
- R (Package: bear): Open-source tool for academic and small sponsors
Case Study: Failed BE Due to CI Just Missing the Limit
A study evaluating a generic extended-release antidepressant showed a Cmax GMR of 94%, with a 90% CI of 79.6% to 112.8%. Despite a good match on AUC, the lower CI limit fell just below 80%, leading to a failed BE conclusion. The sponsor later adjusted the formulation and repeated the study successfully.
Conclusion: CI Is the Regulatory Benchmark for Bioequivalence
The 90% confidence interval rule is not a statistical preference—it’s a regulatory mandate for establishing therapeutic equivalence. By understanding its theoretical foundation, calculation methods, and potential adjustments, pharma and clinical professionals can design, analyze, and interpret BA/BE studies with precision and compliance. A well-constructed CI speaks louder than point estimates or p-values when it comes to regulatory approvals.